Psoriatic juvenile idiopathic arthritis: A tale of two subgroups

Current Opinion in Rheumatology

Volumn 23, Issue 5, 2011, Pages 437-443

  Stoll, Matthew L ^a,b   Punaro, Marilynn ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

Author keywords

age of onset; juvenile idiopathic arthritis; psoriatic arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ANTINUCLEAR ANTIBODY; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; HLA B27 ANTIGEN; HLA DR5 ANTIGEN; INFLIXIMAB; LEFLUNOMIDE; LEUKOCYTE ANTIGEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; AUTOIMMUNITY; CLINICAL TRIAL; COLON RESECTION; CROHN DISEASE; DACTYLITIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG APPROVAL; ENTERITIS; ENTHESITIS; FAMILY HISTORY; FOLLOW UP; GENETIC HETEROGENEITY; HUMAN; IMMUNE RESPONSE; INTERPHALANGEAL JOINT; JUVENILE RHEUMATOID ARTHRITIS; LIMB DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SACROILIITIS; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; SYNOVITIS; SYNOVIUM; TENOSYNOVITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

AGE OF ONSET; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, PSORIATIC; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; SPONDYLARTHRITIS;

EID: 80052031810     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328348b278     Document Type: Review

References (89)

1. Peterson LS, Mason T, Nelson AM, et al. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993.
2. Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 1996; 23:1981-1987. (Pubitemid 26376128)
3. Krumrey-Langkammerer M, Hafner R. Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol 2001; 28:2544-2547. (Pubitemid 33031989)
4. Danner S, Sordet C, Terzic J, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol 2006; 33:1377-1381. (Pubitemid 44025153)
5. Stoll ML, Nigrovic PA. Subpopulations within juvenile psoriatic arthritis: a review of the literature. Clin Dev Immunol 2006; 13:377-380. (Pubitemid 44950055)
6. Nigrovic PA. Juvenile psoriatic arthritis: bathwater or baby? J Rheumatol 2009; 36:1861-1863.
7. Petty RE. Juvenile psoriatic arthritis, or juvenile arthritis with psoriasis? Clin Exp Rheumatol 1994; 12 (SUPPL 10):S55-S58.
8. Martini A. Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol 2003; 30:1900-1903. (Pubitemid 37075533)
9. Butbul YA, Tyrrell PN, Schneider R, et al. Comparison of patients with juvenile psoriatic arthritis and nonpsoriatic juvenile idiopathic arthritis: how different are they? J Rheumatol 2009; 36:2033-2041.
10. Stoll ML, Zurakowski D, Nigrovic LE, et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum 2006; 54:3564-3572. (Pubitemid 44737168)
11. Ansell BM, Bywaters EG. Diagnosis of 'probable' Still's disease and its outcome. Ann Rheum Dis 1962; 21:253-262.
12. Lambert JR, Ansell BM, Stephenson E, Wright V. Psoriatic arthritis in childhood. Clin Rheum Dis 1976; 2:339-352.
13. Calabro JJ. Psoriatic arthritis in children. Arthritis Rheum 1977; 20 (S):415-416.
14. Shore A, Ansell BM. Juvenile psoriatic arthritis: an analysis of 60 cases. J Pediatr 1982; 100:529-535. (Pubitemid 12136020)
15. Sills EM. Psoriatic arthritis in childhood. Johns Hopkins Med J 1980; 146:49-53. (Pubitemid 10187452)
16. Hamilton ML, Gladman DD, Shore A, et al. Juvenile psoriatic arthritis and HLA antigens. Ann Rheum Dis 1990; 49:694-697. (Pubitemid 20279121)
17. Southwood TR, Petty RE, Malleson PN, et al. Psoriatic arthritis in children. Arthritis Rheum 1989; 32:1007-1013. (Pubitemid 19218380)
18. Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 1995; 22:1566-1569.
19. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31:390-392. (Pubitemid 38160763)
20. Huemer C, Malleson PN, Cabral DA, et al. Patterns of joint involvement at onset differentiate oligoarticular juvenile psoriatic arthritis from pauciarticular juvenile rheumatoid arthritis. J Rheumatol 2002; 29:1531-1535. (Pubitemid 34755623)
21. Flato B, Lien G, Smerdel-Ramoya A, Vinje O. Juvenile psoriatic arthritis: longterm outcome and differentiation from other subtypes of juvenile idiopathic arthritis. J Rheumatol 2009; 36:642-650.
22. StollML, Nigrovic PA, Gotte AC, Punaro M. Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. Clin Exp Rheumatol 2011; 29:582-588.
23. Stoll ML, Lio P, Sundel RP, Nigrovic PA. Comparison of Vancouver and International League of Associations for rheumatology classification criteria for juvenile psoriatic arthritis. Arthritis Rheum 2008; 59:51-58. (Pubitemid 351171878)
24. Ravelli A, Varnier GC, Oliveira S, et al. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum 2011; 63:267-275.
25. Ansell B, Beeson M, Hall P, et al. HLA and juvenile psoriatic arthritis. Br J Rheumatol 1993; 32:836-837. (Pubitemid 23267608)
26. Benjamin M, McGonagle D. The enthesis organ concept and its relevance to the spondyloarthropathies. Adv Exp Med Biol 2009; 649:57-70.
27. McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a 'synovioentheseal complex' and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007; 56: 2482-2491. (Pubitemid 47237267)
28. McGonagle D, Stockwin L, Isaacs J, Emery P. An enthesitis based model for the pathogenesis of spondyloarthropathy. Additive effects of microbial adjuvant and biomechanical factors at disease sites. J Rheumatol 2001; 28:2155-2159. (Pubitemid 32947855)
29. McGonagle D. Imaging the joint and enthesis: insights into pathogenesis of psoriatic arthritis. Ann Rheum Dis 2005; 64:ii58-ii60. (Pubitemid 40288524)
30. McGonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol 2009; 23 (SUPPL 1):9-13.
31. Love TJ, Gudjonsson JE, Valdimarsson H, Gudbjornsson B. Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study. Scand J Rheumatol 2010; 39:299-302. This study of 154 adults with PsA demonstrated an association between onycholysis and small joint arthritis.
32. Scarpa R, Soscia E, Peluso R, et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol 2006; 33:1315-1319. (Pubitemid 44025146)
33. McGonagle D, Palmou Fontana N, Tan AL, Benjamin M. Nailing down the genetic and immunological basis for psoriatic disease. Dermatology 2010; 221. (SUPPL 1):15-22.
34. Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis: a high-resolution MRI and histological study. Rheumatology (Oxford) 2007; 46:253-256. (Pubitemid 46189785)
35. Wright V, Watkinson G. The arthritis of ulcerative colitis. Medicine (Baltimore) 1959; 38:243-262.
36. Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, et al. Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann Rheum Dis 1978; 37:33-35. (Pubitemid 8371820)
37. Passo MH, Fitzgerald JF, Brandt KD. Arthritis associated with inflammatory bowel disease in children: relationship of joint disease to activity and severity of bowel lesion. Dig Dis Sci 1986; 31:492-497. (Pubitemid 16085572)
38. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease: a prospective study of 792 patients. J Clin Gastroenterol 1996; 23:29-34. (Pubitemid 26244497)
39. Simenon G, Van Gossum A, Adler M, et al. Macroscopic and microscopic gut lesions in seronegative spondyloarthropathies. J Rheumatol 1990; 17:1491-1494.
40. Mielants H, Veys EM, Goemaere S, et al. Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology: a prospective study. J Rheumatol 1991; 18:1542-1551.
41. Porzio V, Biasi G, Corrado A, et al. Intestinal histological and ultrastructural inflammatory changes in spondyloarthropathy and rheumatoid arthritis. Scand J Rheumatol 1997; 26:92-98. (Pubitemid 27168739)
42. Altomonte L, Zoli A, Veneziani A, et al. Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies. Clin Rheumatol 1994; 13:565-570. (Pubitemid 24382789)
43. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995; 22:2279-2284.
44. Brooke BN. Outcome of surgery for ulcerative colitis. Lancet 1956; 271: 532-536.
45. McGovern DP, Gardet A, Torkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42:332-337.
46. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40:955-962.
47. Reveille JD, Sims AM, Danoy P, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 2010; 42:123-127.
48. Brown MA. Genetics of ankylosing spondylitis. Curr Opin Rheumatol 2010; 22:126-132.
49. Laukens D, Peeters H, Marichal D, et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis 2005; 64:930-935. (Pubitemid 40733921)
50. Stoll ML. Interactions of the innate and adaptive arms of the immune system in the pathogenetis of spondyloarthritis. Clin Exp Rheumatol 2011; 29:322-330. This review proposes mechanisms discussing interactions of innate and adaptive immunity in SpA.
51. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3:55-78.
52. Schatteman L, Mielants H, Veys EM, et al. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol 1995; 22:680-683.
53. Murray KJ, Moroldo MB, Donnelly P, et al. Age-specific effects of juvenile rheumatoid arthritis-associated HLA alleles. Arthritis Rheum 1999; 42:1843-1853. (Pubitemid 30257748)
54. Miller ML, Fraser PA, Jackson JM, et al. Inherited predisposition to iridocyclitis with juvenile rheumatoid arthritis: selectivity among HLA-DR5 haplotypes. Proc Natl Acad Sci USA 1984; 81:3539-3542. (Pubitemid 14122709)
55. Hall PJ, Burman SJ, Laurent MR, et al. Genetic susceptibility to early onset pauciarticular juvenile chronic arthritis: a study of HLA and complement markers in 158 British patients. Ann Rheum Dis 1986; 45:464-474. (Pubitemid 16058761)
56. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34:1218-1227.
57. Amor B, Dougados M, Mijiyawa M:. [Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic 1990; 57:85-89.
58. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68:777-783.
59. Benjamin M, McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J Anat 2001; 199:503-526. (Pubitemid 33094612)
60. McGonagle D, Benjamin M, Tan AL. The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? Curr Opin Rheumatol 2009; 21:340-347.
61. Jevtic V, Watt I, Rozman B, et al. Distinctive radiological features of small hand joints in rheumatoid arthritis and seronegative spondyloarthritis demonstrated by contrast-enhanced (Gd-DTPA) magnetic resonance imaging. Skeletal Radiol 1995; 24:351-355.
62. Olivieri I, Salvarani C, Cantini F, et al. Fast spin echo-T2-weighted sequences with fat saturation in dactylitis of spondylarthritis: no evidence of entheseal involvement of the flexor digitorum tendons. Arthritis Rheum 2002; 46:2964-2967. (Pubitemid 35315889)
63. Healy PJ, Groves C, Chandramohan M, Helliwell PS. MRI changes in psoriatic dactylitis: extent of pathology, relationship to tenderness and correlation with clinical indices. Rheumatology (Oxford) 2008; 47:92-95. (Pubitemid 350286271)
64. Wakefield RJ, O'Connor PJ, Conaghan PG, et al. Finger tendon disease in untreated early rheumatoid arthritis: a comparison of ultrasound and magnetic resonance imaging. Arthritis Rheum 2007; 57:1158-1164. (Pubitemid 47585461)
65. Eshed I, Feist E, Althoff CE, et al. Tenosynovitis of the flexor tendons of the hand detected by MRI: an early indicator of rheumatoid arthritis. Rheumatology (Oxford) 2009; 48:887-891.
66. Marzo-Ortega H, Tanner SF, Rhodes LA, et al. Magnetic resonance imaging in the assessment of metacarpophalangeal joint disease in early psoriatic and rheumatoid arthritis. Scand J Rheumatol 2009; 38:79-83.
67. Stoll ML, Bhore R, Dempsey-Robertson M, Punaro M. Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. J Rheumatol 2010; 37:2402-2408. This retrospective study of children with ERA identified that hip arthritis was a risk factor for sacroiliitis, whereas the presence of dactylitis may be protective.
68. Flato B, Hoffmann-Vold AM, Reiff A, et al. Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum 2006; 54:3573-3582. (Pubitemid 44737169)
69. Pagnini I, Savelli S, Matucci-Cerinic M, et al. Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. J Rheumatol 2010; 37:2395-2401.
70. Otten MH, Prince FH, Ten Cate R, et al. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective? Ann Rheum Dis 2011; 70:337-340.
71. Helliwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs: comparison of drugs and adverse reactions. J Rheumatol 2008; 35:472-476. (Pubitemid 351374424)
72. Scarpa R, Peluso R, Atteno M, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol 2008; 27:823-826.
73. Kingsley GH, Kowalczyk A, Taylor H, et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial [abstract]. Arth Rheum 2010; 62:S277. This randomized controlled trial of methotrexate (MTX) in PsA showed that MTX improved physician and patient global scores but did not affect the swollen joint count or any of the commonly used outcome measures, including the ACR20 or DAS28.
74. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying antirheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008; 67:855-859. (Pubitemid 351829388)
75. Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005; 64:859-864. (Pubitemid 40733909)
76. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009; 68:702-709.
77. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35:869-876. (Pubitemid 351747130)
78. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a newhuman tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60:976-986.
79. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50:2264-2272. (Pubitemid 38924405)
80. Brodszky V, Pentek M, Gulacsi L. Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment. Scand J Rheumatol 2008; 37:399-400.
81. Atteno M, Peluso R, Costa L, et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 2010; 29:399-403.
82. Mease P, Genovese MC, Gladstein G, et al.: Abatacept in the treatment of patients with psoriatic arthritis: results of a double-blind, randomized, placebocontrolled phase 2 trial. Arthritis Rheum 2011; 63:939-948.
83. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006; 54:1638-1645.
84. Papp KA, Caro I, Leung HM, et al. Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 2007; 11:57-66.
85. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633-640.
86. Jung N, Hellmann M, Hoheisel R, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 2010; 29:1169-1173. An open label trial, this was the first study of anakinra in PsA. It showed that only six of 20 completed 20 weeks of treatment, with 13 dropping out due to inefficacy; only six patients continuously met the primary outcome measure of a PsARC response for all 24 weeks.
87. Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007; 66:419-421. (Pubitemid 46579648)
88. Wesolowska H. Clinical course of psoriatic arthropathy in children. Mater Med Pol 1985; 17:185-187.
89. McGonagle D, Aziz A, Dickie LJ, McDermott MF. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res 2009.